Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Sickle Cell Disease Treatment Market

Sickle Cell Disease Treatment Market Share

Report ID: GMI5697
Published Date: May 2023
Report Format: PDF

Download Free Sample

Sickle Cell Disease Treatment Market Share

The key players in sickle cell disease treatment market are :

Pfizer Inc
Novartis AG
Emmaus Medical Inc
Medunik USA Inc.
Bristol-Myers Squibb Company
Bluebird Bio, Inc
Agios Pharmaceuticals
CRISPR Therapeutics
Vifor Pharma
Editas Medicine Inc.

These companies are implementing several strategies such as collaborations, acquisitions, partnerships, mergers, and product launches, etc. to maintain a competitive edge in the industry.

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global market for sickle cell disease treatment was worth around USD 2.38 billion in 2022 and is poised to depict a 12.6% CAGR over 2023-2032 owing to the increasing R&D activities regarding sickle cell disease treatment.

The sickle cell anemia segment accounted for the largest market share in 2022 and will expand significantly through the forecast period owing to the high prevalence of sickle cell anemia.

North American market for sickle cell disease industry held the highest revenue share and is set to grow exponentially on account of increasing investments in R&D for developing new drugs treating sickle cell disease.

Pfizer Inc., Novartis AG, Emmaus Medical Inc., Medunik USA Inc., Bristol-Myers Squibb Company, Bluebird Bio, Inc., Agios Pharmaceuticals, CRISPR Therapeutics, Vifor Pharma, and Editas Medicine Inc. are some of the major companies operating in the sickle cell disease treatment business.